President Donald Trump pledged to lower drug costs by forcing companies to disclose their list prices in ads. But would the plan have even worked in the first place?
A new rule will soon require most drug ads on TV to state the drug's list price. Here's what the science says about how people will likely react.
Scientists have studied the potential for ketamine to treat severe depression for years, but this is the first time the FDA has indicated its use as an antidepressant.
The House Oversight and Reform Committee announced on Monday the launch of an investigation into the pharmaceutical industry's pricing practices.
Aid Access will mail the two-drug cocktail used across the world to women in the United States.
After making a tool that tracks how well drug testers follow U.S. law, researchers turned to an even bigger market for drug trials: the European Union.
Too often, doctors aren't using sound science when they prescribe a drug for unapproved uses, a new study finds.
Medicare has increased oversight of its prescription drug program but many holes remain, allowing fraud and abuse to proliferate. Questionable practices were found at 1,400 pharmacies, which collectively billed Medicare $2.3 billion in 2014.
Medicare gives itself the power to ban physicians if they prescribe medications in abusive ways.
A new report finds that more than half of insurance companies in Medicare’s drug program haven’t reported fraud cases to the government. The findings echo an earlier investigation that found fraud flourishing in the program.
As Medicare considers banning doctors who pose a “threat to the health or safety” of patients, it plans to consider an array of factors.
Action follows ProPublica’s investigative series detailing inappropriate and wasteful prescribing and fraud in the nation’s biggest prescription drug program.
Action comes after ProPublica uses the government’s own data to find patterns of dangerous prescribing, waste, and potential fraud in Medicare Part D.
After a May report finding a third of the malaria pills inspected in Asia and Africa were counterfeit, observers piled on pharmaceutical companies in India and China as likely bad guys. But the truth is a little harder to swallow.